Most conversations about hair loss live at the symptom level. The hairline recedes. The crown thins. The shedding gets worse. These observations are accurate, but they describe the visible end product of a much more interesting story unfolding two millimeters below the surface of the scalp — where four or five molecular pathways, none of which the average user has ever heard of, are interacting in ways that determine whether a follicle keeps producing terminal hair or stops.
This article is a tour of those pathways. It is the kind of explanation a dermatologist would give you if you had two hours instead of fifteen minutes — the actual biology of pattern hair loss, the upstream signals that drive it, and the reason every meaningful treatment is targeting one or more of these mechanisms rather than the hairline itself.
The Three-Phase Cycle Every Follicle Runs
Every hair follicle on the human body is a small, semi-autonomous organ that cycles continuously through three phases. Anagen is the active growth phase, during which the dermal papilla is mitotically active, the matrix cells above it proliferate aggressively, and a hair shaft is extruded outward at roughly one centimeter per month. Catagen is a brief, two-to-three-week transition during which the lower follicle regresses, the dermal papilla detaches, and the hair shaft is severed from its blood supply. Telogen is the resting phase, typically lasting two to four months, during which the dermal papilla sits quiescent before signaling the next anagen cycle to begin.
In healthy scalp tissue, roughly 85 to 90 percent of follicles are in anagen, 1 to 2 percent are in catagen, and 10 to 15 percent are in telogen at any given moment. In pattern hair loss, the ratio shifts: anagen shortens, telogen lengthens, and the proportion of follicles sitting dormant at any given time progressively increases. The pathways below are the upstream drivers of that shift.
The Androgen Pathway: DHT And The Receptor Cascade
The best-understood driver of pattern hair loss is the androgen pathway. Testosterone, produced systemically, is converted into dihydrotestosterone (DHT) by the enzyme 5-alpha-reductase. DHT then binds to the androgen receptor expressed on susceptible follicles — primarily those at the frontal hairline, temples, and crown — initiating a gene-expression cascade that progressively shortens the anagen phase and miniaturizes the follicle over successive cycles.1
Two details about this pathway often get lost in popular summaries. The first is that DHT does not damage the follicle directly. It binds to the receptor, the receptor migrates to the nucleus, and the resulting transcriptional changes alter the production of dozens of downstream signaling molecules — many of which act on the dermal papilla itself. The miniaturization is downstream of those secondary signals, not of DHT in isolation.
The second is that susceptibility to the cascade is genetically determined and follicle-specific. Follicles at the back and sides of the scalp — the donor zone used in transplantation — express the androgen receptor at lower levels and are therefore largely unaffected by DHT, which is why those follicles continue producing terminal hair even in late-stage pattern loss. The same person has hair-keeping follicles and hair-losing follicles on the same scalp, distinguished primarily by their receptor expression profile.
The Wnt/β-Catenin Pathway: The Growth Switch
If the androgen pathway is the upstream driver of pattern hair loss, the Wnt/β-catenin pathway is the downstream switch that determines whether a follicle re-enters anagen at all. The pathway is named after the Wnt family of secreted glycoproteins that bind to surface receptors and ultimately stabilize β-catenin — a transcription factor whose accumulation in dermal papilla cells signals the follicle to begin a new growth phase.
Wnt signaling has been demonstrated to be essential for maintaining the hair-inducing activity of the dermal papilla. In experimental models, blocking Wnt signaling in the dermal papilla causes follicles to lose their capacity to initiate new hair growth altogether.2 In pattern hair loss, the secondary signals downstream of androgen-receptor activation include suppression of Wnt/β-catenin activity, which is a major mechanistic reason follicles get stuck in telogen and fail to re-enter anagen.
This is the pathway most directly engaged by interventions that work at the dermal papilla level — copper peptides, certain growth factors, and the regenerative signaling that follows microneedling all act in part by re-enabling Wnt/β-catenin activity in follicles where it has been suppressed.
The Prostaglandin Pathway: PGD2 And The Brake Pedal
One of the more important discoveries of the last fifteen years in hair biology is the role of prostaglandin D2 (PGD2) in pattern hair loss. In a landmark 2012 study, researchers at the University of Pennsylvania demonstrated that PGD2 is dramatically elevated in the bald scalp of men with androgenetic alopecia — by a factor of three or more compared to haired scalp — and that PGD2 binding to its receptor on follicular cells directly inhibits hair growth.3
The finding shifted the field's understanding of the disease. PGD2 is essentially a brake pedal: a molecule whose elevation suppresses follicular activity independent of any other upstream signal. The presence of elevated PGD2 in affected scalp tissue means that even if you reduced DHT, restored Wnt signaling, and improved every other variable, the prostaglandin brake would still be applied. This is one of the reasons monotherapy approaches — targeting only one pathway — produce partial rather than complete results.
The prostaglandin pathway is now an active area of pharmaceutical research, with several investigational compounds aimed at PGD2 receptor antagonism in clinical trials. For now, the practical implication is that any rational protocol should acknowledge that multiple pathways are simultaneously suppressing follicular activity, and address as many of them as is realistic.
The Inflammatory Pathway: Microinflammation And Fibrosis
Histological examination of scalp tissue from patients with pattern hair loss reveals a finding that long predates visible thinning: a low-grade lymphocytic infiltrate around the upper portion of affected follicles, accompanied by progressive fibrosis of the perifollicular sheath.4 The phenomenon, originally described in the late 1990s and now consistently documented across decades of research, is sometimes called "microinflammation" to distinguish it from the more aggressive inflammatory response seen in conditions like alopecia areata.
The mechanistic significance is twofold. First, the immune infiltrate releases cytokines that themselves suppress follicular activity and contribute to the miniaturization process. Second, the resulting perifollicular fibrosis physically constrains the follicle, restricting blood flow and limiting the space available for a healthy terminal hair shaft. By the time visible thinning is established, the affected regions of scalp are often already partially fibrotic, which is one reason late-stage interventions are less reversible than early-stage ones.
This pathway is increasingly recognized as a primary therapeutic target rather than a downstream consequence. Topical antifungals like ketoconazole, anti-inflammatory peptides, and topical antioxidants all act in part by reducing the perifollicular inflammatory burden.
The Vascular Pathway: Microcirculation And The Dermal Papilla
The dermal papilla is one of the most metabolically demanding cell populations in the human body. Producing a terminal hair shaft at one centimeter per month requires consistent delivery of amino acids, oxygen, and trace minerals through the perifollicular capillary network. As pattern hair loss progresses, that capillary network thins. The vasculature surrounding miniaturizing follicles involutes, the dermal papilla's metabolic supply contracts, and the follicle's capacity to produce a thick hair shaft drops in proportion.
Whether vascular involution is upstream or downstream of the other pathways is still debated. Reduced blood flow may contribute to miniaturization in some patients and result from it in others. What is clear is that interventions which improve perifollicular microcirculation — caffeine, certain peptides, mechanical microneedling, low-level laser therapy — produce measurable improvements in follicular activity even when no other variable is changed.
The Stem Cell Layer: What Pattern Loss Doesn't Actually Destroy
One of the more hopeful findings in the modern hair-loss literature is that pattern hair loss does not eliminate follicles. A 2011 study from the University of Pennsylvania demonstrated that the bald scalp of men with androgenetic alopecia retains its full complement of follicular stem cells — but lacks the activated progenitor cells that those stem cells would normally produce.5 The follicles are still there; the activation signal isn't reaching them.
This is the biological foundation for therapeutic optimism. If miniaturized follicles were destroyed, regrowth would be impossible. They aren't. They are dormant, embedded in increasingly hostile tissue, and waiting for the right combination of upstream signals to re-enter active cycling.6 Every effective intervention is, in some way, restoring those signals.
The Bottom Line
Pattern hair loss is not a single-pathway disease. It is the convergence of an androgen-driven cascade, a suppressed Wnt/β-catenin growth switch, an elevated prostaglandin brake, chronic perifollicular microinflammation, and progressive vascular involution — all acting on a follicle whose stem-cell population is intact but whose activation signals have been progressively muted. Understanding the biology is not just academic. It is the reason single-active products produce partial results, why multi-pathway protocols outperform them, and why early intervention — applied while the tissue environment is still favorable — produces dramatically better outcomes than late intervention. The pathways are knowable. The molecules are characterized. And the practical implication for anyone watching their hairline change is that the underlying biology is far more tractable than it looks from the outside.
